Other

Roche to pay $7.1 bn for Telavant Holdings

Swiss pharmaceutical group Roche said Monday it will pay $7.1 billion to buy Telavant Holdings, a group developing new treatments for inflammatory bowel diseases.

Medical research

Developing a less invasive test for inflammatory bowel disease

Millions of Americans have inflammatory bowel disease (IBD), which occurs in one of two forms: Crohn's disease or ulcerative colitis. Though the two have similar symptoms, they require different treatment strategies, and ...

page 4 from 39